Stimulation test in the follow-up of thyroid cancer: Plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values

Nuclear Medicine Communications

Volumn 28, Issue 4, 2007, Pages 257-259

  Zanotti Fregonara, Paolo ^a   Duron, Françoise ^a   Keller, Isabelle ^a   Khoury, Alexandre ^a   Devaux, Jean Yves ^a   Hindié, Elif ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Body weight; RhTSH; TSH plasma levels

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROTROPIN;

ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROVOCATION TEST; THYROID CANCER; THYROTROPIN BLOOD LEVEL;

BIOLOGICAL MARKERS; BODY WEIGHT; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; STATISTICS; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 34247591084     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32804c58c2     Document Type: Article

References (11)

1. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma [Review]. J Clin Endocrinol Metab 2003; 88:1433-1441.
2. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective [Review]. Eur J Endocrinol 2004; 150:105-112.
3. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SL, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. J Clin Endocrinol Metab 2006; 91:878-884.
4. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337:888-896.
5. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SL, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877-3885.
6. Edmonds CJ, Hayes S, Kermode JC, Thompson BD, et al. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977; 50:799-807.
7. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New Engl J Med 1998; 338:297-306.
8. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, Kievit J, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004; 61:61-74.
9. +/I symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999; 84:3228-3234.
10. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, et al. Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90:4047-4050.
11. Vitale G, Lupoli GA, Ciccarelli A, Lucariello A, Fittipaldi MR, Fonderico F, et al. Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J Clin Endocrinol Metab 2003; 88:1319-1322.